top of page
Expertise & Vision
Leadership Team
Ed Cable, PhD
Chief Executive Officer
Glenn Croston, PhD
Chief Operating Officer
Kazik Wisniewski, PhD
Chief Science Officer
John Lucas, PhD, JD
Legal Counsel
Our Principles
Guided by Clinical Excellence & Patient Safety
Scientific Rigor
We employ uncompromising clinical standards in developing our V1aR partial agonists, ensuring every therapeutic milestone is backed by robust data and precision hepatology.
Patient-Centered Safety
Safety is our fundamental directive. We are dedicated to providing cirrhosis patients with transformative therapies that prioritize stability and long-term well-being.
Innovative Impact
By targeting the root causes of circulatory dysfunction, we strive to reverse vasodilation and significantly reduce complications in the decompensated cirrhosis space.
bottom of page